GMOV - ETF AI Analysis

Top Page

GMO US Value ETF (GMOV)

Rating:73Outperform

Price Target:―

GMOV’s rating suggests it is a solid, but not flawless, value-focused ETF built around large, established companies. Strong holdings like Alphabet, Johnson & Johnson, Merck, and Verizon support the fund’s quality through robust financial performance, positive earnings calls, and strategic growth initiatives. However, exposure to energy names like Chevron and Exxon Mobil, which face revenue and cash flow challenges, and company-specific risks such as high debt or regulatory and legal issues, highlight the main risk of relying heavily on a concentrated group of large U.S. sectors and their evolving fundamentals.

Positive Factors

Solid Recent Performance Trend

The ETF has shown steady gains over the last three months, indicating improving momentum in its value-focused strategy.

Diversified Sector Mix

Holdings are spread across financials, health care, communication services, consumer sectors, energy, and technology, which helps reduce reliance on any single industry.

Strong Core Holdings

Several of the largest positions, such as Exxon Mobil, Chevron, Johnson & Johnson, and Merck, have delivered strong year-to-date results that support the fund’s overall performance.

Negative Factors

Moderately High Expense Ratio

The fund’s expense ratio is on the higher side for an ETF, which can gradually eat into long-term returns compared with lower-cost alternatives.

Concentrated U.S. Exposure

With almost all assets invested in U.S. companies, the ETF offers little geographic diversification and is heavily tied to the U.S. market’s fortunes.

Mixed Performance Among Top Holdings

Some major positions, including Meta Platforms, Bank of America, and Verizon, have shown weak year-to-date performance, which can drag on the fund if this trend continues.

GMOV vs. SPDR S&P 500 ETF (SPY)

AUM79.46M

RegionNorth America

Expense Ratio0.50%

Beta0.78

IssuerGMO

Inception DateOct 28, 2024

Dividend Yield1.86%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume18,785

30 Day Avg. Volume20,101

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

31.68

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering166

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

GMOV Summary

GMOV is the GMO US Value ETF, which invests in a wide range of U.S. stocks with a focus on companies that appear cheap compared with their business strength. It doesn’t track a set index, but follows a value theme across the total U.S. market, with big positions in well-known names like Exxon Mobil and Johnson & Johnson. Investors might consider GMOV if they want diversified exposure to U.S. stocks while tilting toward value companies that could have room to grow. A key risk is that value stocks can lag the overall market for long periods and the share price can go up and down with market swings.

How much will it cost me?The GMO US Value ETF (GMOV) has an expense ratio of 0.5%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because the fund is actively managed, relying on expert analysts to select undervalued stocks with strong growth potential.

What would affect this ETF?The GMO US Value ETF could benefit from a favorable economic environment that supports undervalued stocks, particularly in sectors like Financials and Health Care, which are heavily represented in its portfolio. However, rising interest rates or regulatory changes in key sectors such as Technology and Energy could negatively impact the ETF's performance. Additionally, shifts in consumer spending or market sentiment might influence the value of top holdings like Johnson & Johnson and Meta Platforms.

GMOV Top 10 Holdings

GMOV is leaning hard into classic U.S. value, with financials, health care, and energy doing much of the heavy lifting. Exxon and Chevron are powering ahead as energy stays in favor, while Johnson & Johnson and Merck give the fund a steady, defensive backbone with rising health care momentum. Alphabet adds a touch of Big Tech growth that’s been climbing nicely, but Meta is losing steam and acting as a bit of a drag. Bank of America and Verizon are more mixed, reflecting the bumpier side of this value-focused, U.S.-only story.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
XOM	Exxon Mobil	4.11%	$3.26M	$635.44B	36.39%	74 Outperform
JNJ	Johnson & Johnson	3.86%	$3.07M	$590.40B	52.13%	78 Outperform
MRK	Merck & Company	3.07%	$2.44M	$301.96B	36.16%	80 Outperform
GOOGL	Alphabet Class A	2.89%	$2.29M	$3.67T	68.57%	85 Outperform
VZ	Verizon	2.61%	$2.07M	$202.66B	13.75%	81 Outperform
BAC	Bank of America	2.43%	$1.93M	$384.86B	17.76%	72 Outperform
CVX	Chevron	2.41%	$1.91M	$370.23B	17.75%	71 Outperform
PG	Procter & Gamble	2.23%	$1.77M	$364.54B	-6.86%	69 Neutral
PFE	Pfizer	2.21%	$1.75M	$155.62B	2.13%	74 Outperform
CMCSA	Comcast	2.09%	$1.65M	$113.69B	-13.52%	74 Outperform

GMOV Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

28.25

Positive

100DMA

27.28

Positive

200DMA

26.15

Positive

Market Momentum

MACD

0.35

Positive

RSI

62.78

Neutral

STOCH

45.64

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GMOV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 28.95, equal to the 50-day MA of 28.25, and equal to the 200-day MA of 26.15, indicating a bullish trend. The MACD of 0.35 indicates Positive momentum. The RSI at 62.78 is Neutral, neither overbought nor oversold. The STOCH value of 45.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GMOV.

GMOV Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
GMOV	―	―	$79.46M	0.50%	―
BAMV	―	―	$98.36M	0.91%	―
TCV	―	―	$93.47M	0.85%	―
VUSV	―	―	$54.96M	0.30%	―
GVLE	―	―	$43.22M	0.45%	―
CVAR	―	―	$39.94M	0.87%	―

Performance Comparison

GMOV

GMO US Value ETF

29.35

4.45

17.87%

BAMV

Brookstone Value Stock ETF

―

TCV

Towle Value ETF

―

VUSV

Vanguard Wellington U.S. Value Active ETF

―

GVLE

Goldman Sachs Value Opportunities ETF

―

CVAR

Cultivar ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents